Harrow: Q3 Needs To Prove The Turnaround Is Real

Harrow remains a cautious Buy despite a 20% stock decline and missing H1 revenue targets. Full-year guidance requires record-high revenue in both Q3 and Q4, alongside positive EBITDA; improved payer coverage for VEVYE, better pricing and reimbursement for IHEEZO, and the TYRVAYA acquisition provide potential H2 tailwinds.

Analysis

The setup is an execution-risk trade, not yet a clean growth-buy: a back-end-loaded forecast raises the cost of even a modest launch or reimbursement delay, while the stock’s decline alone says nothing about valuation support. Improved coverage and reimbursement can expand eligible demand, but the economic test is net product revenue after discounts and the selling costs needed to convert access into prescriptions. TYRVAYA adds potential, not near-term proof of contribution. In the next 1–3 months, quarterly product-level revenue, gross-to-net realization and operating expense discipline matter more than access announcements. Over 6–18 months, sustained uptake could validate a broader commercial platform; weak conversion could expose recurring launch costs and undermine confidence in guidance. The contrarian opportunity is that a sharp drawdown may already reflect skepticism, but there is insufficient valuation or cash-flow data here to call it overdone. Treat management’s full-year outlook as conditional, not as a floor.

Key Decisions for Investors

• Avoid adding solely because HROW is down; wait for Q3 evidence that product-level net sales are converting improved access into revenue and that EBITDA is tracking toward the required run rate.
• For investors seeking exposure, consider a small, staged long only after confirmation in reported revenue and EBITDA; define the thesis as invalidated by a material guidance reduction or another quarter showing weak conversion despite the cited access and pricing tailwinds.
• Track VEVYE and IHEEZO net revenue, reimbursement realization and commercial spending separately where disclosed. Coverage announcements without prescription or revenue follow-through are a watch signal, not a catalyst to underwrite.
• Reassess after the next earnings release: upside requires both commercial traction and cost control; a miss would likely renew pressure on guidance credibility. No valuation-based price target is supportable from the supplied information.